New trial data reveals atebimetinib combined with gemcitabine/nab-paclitaxel significantly improves survival rates in ...

During a live event, Saby George, MD, and participants discussed tolerability concerns in patients with recurrent renal cell ...

Cilta-cel therapy significantly enhances survival rates in lenalidomide-refractory multiple myeloma, outperforming standard ...

During a live event, Binod Dhakal, MD, and participants discussed their experience using selinexor in the second line and ...

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted precision medicine strategies.

During a live event, Chandler H. Park, MD, and participants discuss NCCN guidelines and TiNivo-2 data for second-line renal ...

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted precision medicine strategies.

FDA updates talazoparib and enzalutamide labeling, confirming survival benefits for HRR-mutated mCRPC, while excluding ...

During a live event, Mojtaba Akhtari, MD, discussed the goals and treatment approach for patients with low-risk polycythemia ...

Discover essential strategies for physicians to enhance team management in medical practices, fostering efficiency and ...

Advancements in cancer care focus on precise detection of measurable residual disease, enhancing monitoring and relapse ...

Tabelecleucel shows promising efficacy in treating EBV-positive PTLD, offering hope for patients resistant to previous ...